

RESEARCH NOTE & MARKET BRIEF

# Unlocking China's Longevity & Biotech Market:

A Strategic Gateway for Swiss & European Health Companies

FTE® Capital Markets Summit | Lake Zurich | 17–18 & 26–27 March 2026

## Executive Summary

---

The convergence of European scientific excellence and China's rapidly expanding longevity and biotech ecosystem represents one of the most compelling cross-border opportunities in life sciences today. China has emerged as the world's second-largest biopharmaceutical market, with a healthcare infrastructure undergoing a generational transformation — one that actively courts foreign innovation in precision medicine, anti-aging therapeutics, regenerative medicine, and digital health.

For Swiss and European health companies seeking to access this market, the FTE® Capital Markets Summit at Lake Zurich — held across two flagship sessions on 17–18 March and 26–27 March 2026 — offers a rare, structured pathway into China's biotech and longevity investment ecosystem. Anchored by the participation of Elie Haddad, CEO of BioCities at BCD Holdings, and a curated network of Chinese biotech investors, the Summit provides a direct bridge between European innovation and Chinese capital. The Summit will also feature the presentation of the ALEPH Health Sub Fund — an institutional vehicle providing structured access to a curated portfolio of European health and longevity companies.

---

## The China Longevity & Biotech Opportunity: Scale and Momentum

---

China's healthcare transformation is not merely incremental — it is structural. Several macro forces are converging to create exceptional demand for the solutions that Swiss and European companies are best positioned to provide:

 World's largest ageing population — 400M+ citizens over 60 by 2035  
 Biopharmaceutical market projected to exceed USD 400B by 2030

 Rapidly maturing CRO/CDMO infrastructure supporting international partners  
 State policy explicitly supporting longevity, precision medicine & AI health

 Bio City Qingdao — China's 11th largest city, ranked 33rd globally for scientific research, 29 universities, 9 national key laboratories

 NMPA regulatory reform actively accelerating foreign drug approvals

 Deep private equity and sovereign wealth appetite for biotech co-investment

 Cross-border licensing, JV and partnership frameworks increasingly accessible

The longevity sector specifically — encompassing senolytics, NAD+ metabolism, epigenetic reprogramming, stem cell therapies, and AI-driven diagnostics — has attracted extraordinary interest from Chinese investors and government-affiliated research institutes. Swiss and European companies in these fields are regarded with particular esteem, given Europe's heritage in clinical rigour, regulatory standards, and deep-science drug development.

---

## BioCities & BCD Holdings: The Gateway into China's Biomedical Ecosystem

---

Central to the FTE® Summit's China market access proposition is the participation of Elie Haddad, CEO of BioCities, the life sciences urban development and ecosystem platform of BCD Holdings — the developer behind one of the most ambitious and uniquely structured biomedical innovation projects in Asia today.

### Bio City Qingdao — The Flagship Project

BCD's flagship project, Bio City Qingdao, is planned for Qingdao — China's 11th largest city, consistently ranked among China's top 10 science and technology innovation cities and 33rd globally for scientific research. The city hosts 29 universities, 30+ research institutes, and 9 national key laboratories. Bio City Qingdao is the only project in China that combines a children's hospital, an R&D cluster, a business park, a residential area, and a lifestyle community in a single integrated district. The project has the full backing of the provincial government of Shandong — China's second-largest province — making it eligible for additional state funding. It is structured to deliver short-term returns (real estate), medium-term returns (hospital cash flows), and significant long-term upside through R&D, a venture portfolio, and clinical data assets.

China's healthcare and biotech sectors are undergoing structural acceleration driven by policy reform and capital allocation — China has now surpassed the United States in clinical trials and new molecules under development. BCD is positioned at the forefront of this emerging market, with a management team whose CEO was the architect of Riyadh's Biotech City strategy (sitting on Saudi Arabia's national R&D and vaccines committees, chaired by HRH the Crown Prince) and previously served as GM of the largest real estate development company in the GCC. This combination of biotech ecosystem expertise and large-scale development execution is unmatched in the sector.

The project's risk profile is substantially de-risked through government alignment: land is provided at a 50% discount with a four-year deferred payment structure, meaning BCD owns the land upfront and begins payment from the project's own cash flows from Year 4. The land is independently valued at USD 426 million pre-zoning and USD 800 million post-zoning (within nine months). The land underpins a USD 3 billion project being financed in phases over five to six years — with the project expected to become cash flow positive by Year 3. A government pledge of over USD 400 million in tax refunds and benefits to the BCD Hong Kong Holding company further strengthens the investment case. CRCC, a shareholder in BCD Holding (Hong Kong), has committed USD 15 million, and a current equity raise of USD 60 million is underway at the BCD Hong Kong Holding level.

The platform extends well beyond Qingdao. A second Bio City is currently being negotiated in Beijing, with the participation of Alibaba Health and the local government, and a third is planned in Thailand's Eastern Economic Corridor — giving the platform capacity to raise up to USD 1 billion over the near term. BCD's access to the world's leading global biotech clusters — Boston, Singapore, Beijing, Munich, and Cambridge — provides a continuous pipeline of start-ups and partnership opportunities to accelerate each project.

For attending Swiss and European delegates at the FTE® Summit, engagement with BioCities and Elie Haddad opens access to:

- Physical biomedical infrastructure — purpose-built lab space, R&D clusters, manufacturing zones, and hospital networks within government-backed BioCities ecosystems
- Government-aligned market entry — structural advantages including Shandong provincial backing, state financing, USD 400M+ tax incentives, and 50% discounted land with four-year deferred payment
- Investment facilitation — connections to Chinese VCs, family offices, sovereign-linked funds, CRCC, and strategic corporate investors including Alibaba Health
- Commercial partnerships — introductions to Chinese pharmaceutical companies, hospital networks, and health system operators seeking licensed technologies and co-development partners
- Global cluster connectivity — access to BCD's network spanning Boston, Singapore, Beijing, Munich, and Cambridge, accelerating partnership and technology pipeline development

---

## The FTE® Capital Markets Summit: Structure & Format

---

The FTE® Capital Markets Summit is one of Europe's most focused and high-calibre gatherings for health, longevity, and biotech capital formation. Hosted on the shores of Lake Zurich —

Switzerland's global financial heartland — the Summit convenes founders, C-suite executives, institutional investors, family offices, and ecosystem partners in an intimate, curated format designed to generate substantive dialogue and actionable connections.

### Summit Dates & Format — March 2026

Session I: 17–18 March 2026 | Lake Zurich, Switzerland

Session II: 26–27 March 2026 | Lake Zurich, Switzerland

Format: Keynote presentations | Expert panels | Curated roundtables  
One-on-one investor meetings | Networking dinners

Attendance: By invitation — qualified investors, institutional delegates & company executives

The dual-session structure is designed to allow a first cohort of companies and investors to establish relationships and frameworks in the first session, with the second providing a structured follow-up for deeper due diligence, term-sheet discussions, and partnership formalisation. European companies attending both sessions benefit from an accelerated engagement cycle that would typically take many months to replicate through conventional market entry channels.

---

## Featured Speakers & Invited Participants

---

The FTE® Capital Markets Summit brings together a curated faculty of entrepreneurs, investors, and ecosystem builders with direct relevance to the China market access theme. The following confirmed and invited speakers represent the calibre of expertise and connectivity that Summit delegates will engage with across both sessions.

### Confirmed Speakers

#### Elie Haddad

CEO, BioCities | Managing  
Partner, ALEPH Advisors  
BCD Holdings

Elie Haddad is CEO of BioCities and the principal architect of Bio City Qingdao — the only project in China combining a children's hospital, R&D cluster, business park, residential community, and lifestyle infrastructure in a single government-backed district. Prior to BioCities, Elie was CEO of Riyadh Biotech City (chaired by HRH the Crown Prince of Saudi Arabia), sat on Saudi Arabia's national R&D and vaccines committees, and previously served as GM of the largest real estate development company in the GCC — a unique combination of biotech ecosystem expertise and large-scale project execution. Elie also serves as Managing Partner of ALEPH Advisors, a Luxembourg-based securitisation and investment

platform. At the Summit, he will present the BioCities platform and facilitate direct introductions between European health companies and the Chinese biotech and longevity investor ecosystem.

### Peter R. Nicholson

*Founding Partner & GM,  
ALTEKA Global Sàrl | Co-  
founder & CEO, Ohana Health  
| Board Director, Legacy  
Healthcare SA*  
Switzerland-based

Peter Nicholson is one of Europe's most accomplished life sciences business development executives, with a career spanning Amgen, Nestlé Skin Health, Galderma, Dermavant Sciences, and multiple private equity mandates with firms including KKR, Advent International, EQT, and Nordic Capital. He has led or advised on transactions exceeding USD 10 billion in aggregate value across M&A, licensing, and divestitures. A US citizen resident in Switzerland (Chardonne, VD), Peter brings transatlantic biopharma strategy expertise and board-level governance perspective. He currently serves on the Board of Legacy Healthcare SA, co-founded Ohana Health in Geneva, and leads ALTEKA Global — a transaction advisory boutique serving biopharma and medical device companies across Europe and North America.

### Jim Kean

*Co-founder & CEO*  
Molecular You Corporation

Jim Kean is co-founder and CEO of Molecular You, a leading precision medicine and longevity diagnostics company that delivers advanced multi-omic health assessment through a single blood test measuring over 250 biomarkers. Molecular You's AI-driven platform spans 30+ health domains — from longevity biomarkers to chronic disease risk — and is used by both individual subscribers and clinical practices globally. The company has completed a USD 5 million Series A and is expanding internationally, including into Asia. Jim will present Molecular You's precision health platform and its strategic relevance to the Chinese preventive medicine market.

### Rob Fraser

*Co-founder*  
Molecular You Corporation

Rob Fraser is co-founder of Molecular You and a pioneer in applying multi-omics data — including proteomics and metabolomics — to personalised health risk assessment. Rob's scientific leadership has underpinned the development of Molecular You's proprietary biomarker platform, which has received strong third-party validation and major media recognition. He brings deep expertise in translational science and the commercial application of genomics and data-driven diagnostics, making him a compelling voice on the future of longevity medicine and its potential for the Asian market.

### Saad Harati

*Executive | Legacy Healthcare  
SA*  
Legacy Healthcare SA,  
Epalinges, Switzerland

Saad Harati represents Legacy Healthcare SA, a Swiss-based biopharmaceutical company developing first-in-class prescription botanical drugs targeting the USD 100 billion immune and inflammatory disease markets. Legacy's lead asset, Cinainu, is a topical formulation derived from GRAS plant extracts that has demonstrated significant clinical improvement in a Phase 2/3 alopecia areata trial — with no immune-related adverse effects and critically, sustained remission after treatment cessation, a result not seen with existing therapies. Legacy is

poised to begin Phase 3 registration studies in the US and Japan and has an OTC formulation currently commercialised in European test markets.

## Invited Participants & Target Ecosystem

In addition to confirmed speakers, the FTE® Summit has extended invitations to key participants from the Swiss and European Precision Medicine ecosystem — drawing on the deep networks that FTE® Capital Markets has built across the region's leading life science companies and research institutions. Target invitees include senior representatives and decision-makers from companies such as:

### Swiss Ecosystem

Roche Pharmaceuticals (Basel)  
Novartis (Basel)  
Lonza Group  
Molecular Partners AG  
Sophia Genetics  
Debiopharm Group  
EPFL (Lausanne)

### Greek Ecosystem

Genome Ventures (Athens)  
Biosense (Thessaloniki)  
Regenerative Medicine Greece  
Inrastte (Athens)  
University of Crete Precision  
Medicine Center  
Molecular Diagnostics SA  
Biomedical Research  
Foundation of the Academy of  
Athens

### Investors & Funds

ALEPH Advisors (Luxembourg)  
Chinese Biotech VCs & Co-  
investors  
Family Offices with Asia Mandates  
Sovereign-linked Health Funds  
Strategic Corporate Investors

## The ALEPH Health Sub Fund: A Structured Investment Vehicle

The FTE® Capital Markets Summit will feature the formal presentation of the ALEPH Health Sub Fund — a curated, institutional-grade investment vehicle developed by ALEPH Advisors for qualified investors.

The Fund provides structured exposure to a portfolio of high-quality European health and longevity companies at the frontier of biotech, digital medicine, and precision health. Portfolio companies featured in the Fund and presented at the Summit include:

### ALEPH Health Sub Fund — Portfolio Highlights

The following companies represent the calibre of assets within the Fund's portfolio, each of which will be accessible to Summit investors:

- BioCities / BCD Holdings — Integrated biomedical urban platform, China & APAC
- Magnes AG (NUSHU) — AI-powered medical wearables for neurology, ETH Zurich spin-off
- Legacy Healthcare (Cinainu) — First-in-class botanical biopharma, immunology
- Molecular You — Multi-omic precision diagnostics, 250+ biomarkers, AI platform
- Ohana Health — AI-driven training platform for global aged care workforce
- AhRtistry Bio — Next-generation AhR agonist platform for chronic inflammation
- Adoram Therapeutics — Allosteric small molecule drug discovery (University of Geneva licence)
- PharmaRolly — EU GMP-certified medicinal cannabis producer (Macedonia)
- Vita Hydrokultur — Next-gen plant-based bio-manufacturing for skincare actives

ALEPH Advisors is a Luxembourg-based securitisation and investment company offering globally diversified, fully collateralised asset portfolios across loans, equities, bonds, and bespoke securities, managed under robust regulation for transparency, security, and inflation-adjusted returns. The ALEPH Health Sub Fund represents a compelling opportunity for investors seeking curated exposure to European health innovation with an emerging market overlay.

---

## Company Spotlights: Summit Presenting Companies

---

The following company profiles represent a selection of the innovators presenting at the FTE® Capital Markets Summit. Each has been curated for their strategic fit with the China and Asian market access theme, and each will be available for one-on-one engagement with Summit investors and partners.

### Molecular You Corporation

*Predictive, preventive, and precision medicine powered by multi-omics and AI*

**Investment Theme:** Multi-omic health risk assessment delivering personalised longevity and preventive insights

Molecular You delivers advanced health risk assessment through a single blood test measuring 250+ biomarkers via proteomics and metabolomics. Its AI-driven platform identifies root-cause health risks and provides personalised insights across 30+ health domains, spanning longevity, chronic disease management, and early disease prevention. The platform is used by both individuals and clinical practices, supporting a global shift from reactive care to data-driven preventive medicine. Molecular You has completed a USD 5 million Series A and is expanding internationally, including into Asia — a market of exceptional strategic fit given China's growing appetite for precision health and longevity solutions.

- 250+ biomarker coverage via proteomics and metabolomics — clinical-grade analytics
- AI platform with consumer and B2B clinical applications; expanding international footprint including Asia
- Defensible long-term data moats; positioned against superficial wellness offerings with scientific rigour

- Completed USD 5M Series A; strong third-party validation and major media recognition

## Legacy Healthcare SA — Cinainu

*First-in-class prescription botanical drugs for immunology and inflammatory diseases*

**Investment Theme:** Targeting the USD 100B+ immune and inflammatory disease markets with superior safety and durable remission

Legacy Healthcare has developed Cinainu, a topical formulation derived from GRAS plant extracts that modulates inflammatory pathways and restores immune balance. In a Phase 2/3 alopecia areata trial, Cinainu demonstrated significant clinical improvement with no immune-related adverse effects and — critically — sustained remission after treatment cessation, a result not observed with existing therapies including oral JAK inhibitors. Legacy is poised to begin Phase 3 registration studies in the US and Japan. An OTC formulation is already commercialised in European test markets, providing near-term revenue and global scaling optionality. Peter Nicholson (ALTEKA / Board Director, Legacy Healthcare) and Saad Harati will represent Legacy at the Summit.

- FDA (USA) and PDMA (Japan) approved development pathway — Phase 3 ready
- Differentiated versus oral JAK inhibitors, without their black-box warnings
- Peak alopecia areata sales projected at approximately USD 3B; pipeline expansion to dermatitis, psoriasis, oncology fatigue
- Botanical platform supports multi-indication expansion with lower safety and regulatory risk than synthetic immunomodulators

## Who Should Attend: Target Profile for European Companies

The FTE® Summit's China-facing programme is specifically designed for Swiss and European companies at the intersection of life sciences, longevity, and health technology. Ideal delegate companies include those operating in, or adjacent to, the following sectors:

### Longevity Science

Senolytics & senescence  
Epigenetic reprogramming  
NAD+ / metabolic health  
Stem cell & regenerative medicine  
Biomarkers & longevity diagnostics

### Biopharmaceuticals

Oncology & immunotherapy  
Rare & orphan diseases  
Gene & cell therapy  
mRNA & nucleic acid platforms  
Botanical & plant-derived drugs

### Digital & MedTech

AI-driven drug discovery  
Wearables & continuous health monitoring  
Digital therapeutics (DTx)  
Medical devices & implants  
Health data & genomics platforms

Companies need not be at commercial stage to benefit. The Summit welcomes growth-stage and pre-commercial innovators with compelling science, strong IP positions, and a strategic interest in

Chinese partnerships — whether through licensing, co-development, joint ventures, or equity investment.

---

## Why Now? The Strategic Window for Europe-China Health Partnerships

---

### A Strategic Window is Open — and it Will Not Remain So Indefinitely

China's biotech sector has reached a point of institutional maturity at which international partnerships are not merely welcomed — they are actively sought, particularly from European partners who bring clinical credibility, regulatory track records, and technological depth that complement China's manufacturing scale and market access. Chinese investors are deploying capital with greater sophistication, targeting assets with global licensing potential. At the same time, European companies face increasingly competitive domestic funding environments, making international capital diversification strategically urgent.

Switzerland occupies a uniquely advantageous position in this dynamic. As home to some of the world's leading pharmaceutical and biotech companies, Switzerland is regarded by Chinese partners as a mark of scientific quality and regulatory rigour. Swiss companies entering China via structured partnerships — rather than unilateral market entry — are consistently better positioned to achieve favourable terms, protect IP, and build durable commercial relationships.

The FTE® Capital Markets Summit's focus on connecting European innovation with the BioCities ecosystem and Chinese investor community arrives at precisely this inflection point — offering European companies a curated, credible, and efficient pathway to market engagement that would otherwise require years of independent relationship building.

---

## What Attending Companies Can Expect

---

### Key Outcomes for Participating Companies

- Direct, facilitated introductions to Elie Haddad and the BioCities / BCD Holdings team
- Access to Chinese biotech investors, family offices, and strategic corporate partners
- Structured briefings on China market entry pathways, regulatory considerations & partnership structures
- One-on-one meeting programme with pre-qualified investor and partner delegates

- Engagement with Peter Nicholson (ALTEKA), Jim Kean & Rob Fraser (Molecular You), and Saad Harati (Legacy Healthcare)
- Presentation of the ALEPH Health Sub Fund and co-investment structures
- Participation in expert panels on Longevity, Precision Medicine, and Asia-Pacific capital flows
- Invitation to Summit networking dinners — the setting where relationships are truly formed
- Post-Summit facilitation: follow-up introduction support and ecosystem connectivity

---

## Call to Action: Register Now

---

The Chinese longevity and biotech market will be defined, in large part, by the partnerships and platforms established in the next three to five years. Companies that enter now — with the right partners, the right introductions, and the right strategic framing — will enjoy first-mover advantages in licensing terms, co-development economics, and brand positioning within China's health ecosystem.

If your company is working at the frontier of longevity science, biopharmaceuticals, precision diagnostics, or health technology, and you are serious about accessing the Chinese market, the FTE® Capital Markets Summit at Lake Zurich in March 2026 is the most efficient and credible pathway available to you today.

### REGISTER YOUR INTEREST NOW

All Longevity, Biotech, and Health Innovation companies wishing to meet the Partners of the FTE® Capital Markets Summit and be considered for introduction to the Chinese Longevity and Biotech market are invited to register immediately.

*Places are strictly limited and allocated on a first-come, qualified basis.*

**[www.ftecapitalmarkets.com](http://www.ftecapitalmarkets.com)**

FTE® Capital Markets Summit | Lake Zurich | 17–18 & 26–27 March 2026

For company applications, speaking enquiries, and investor introductions, please contact the FTE® Capital Markets team via the website above. Early registration is strongly encouraged — the Summit is structured for depth of engagement, and delegate numbers are intentionally limited to ensure every company has meaningful access to investors and partners.

*This Research Note is prepared for informational and promotional purposes. It does not constitute investment advice. All market data and valuations cited from third-party documents are indicative and unverified. FTE® Capital Markets reserves all rights. For qualified investors and institutional participants only.*